Adaptive Fractionation in Online Adaptive Stereotactic Radiotherapy for Abdominopelvic Lymph Node Oligometastases
Recruiting
N/A
Interventional Study
Lymph Node Oligometastases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 25 (estimated)
- Sponsor
- Joost J. M. E. Nuyttens · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Oligometastases, a state of cancer with up to five metastases, was traditionally treated with systemic treatments like chemotherapy. Treatment with stereotactic body radiotherapy (SBRT) showed a high local control and improved disease-free survival.
The use of SBRT also allows for the deferral of systemic treatment, thereby delaying its potential side effects. SBRT enables the delivery of a high …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Patients with abdominal and/or pelvic lymph node recurrences of solid tumors.
* No more than 5 metastatic lesions in no more than 2 organs and a controlled primary tumor site.
* Diagnostic imaging includes at least a PET scan or CT thorax/abdomen, of which one is not older tha…
Contacts
No contact information available.